

Publications: Duda

Article: Morley, J.F., Duda, J.E.: Dopamine transporter imaging in the evaluation of suspected Parkinson's disease - How and when to use it. *Federal Practitioner* in press.

Trinh, J., Amouri, R., Duda, J.E., Morley, J.F., Read, M., Donald, A., Vilariño-Güell, C., Thompson, C., Szu Tu, C., Gustavsson, E.K., Ben Sassi, S., Hentati, E., Zouari, M., Farhat, E., Nabli, F., Hentati, F., Farrer, M.J.: A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. *Neurobiology of Aging* 35: 1125-31, 2014.

van Steenoven, I., Aarsland, D., Hurtig, H., Chen-Plotkin, A., Duda, J.E., Rick, J., Chahine, L.M., Dahodwala, N., Trojanowski, J.Q., Roalf, D.R., Moberg, P.J., Weintraub, D.: Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease. *Movement Disorders* 29: 1809-15, 2014.

Doty, R.L., Nsoesie, M.T., Chung, I., Osman, A., Pawasarat, I., Caulfield, J., Hurtig, H., Silas, J., Dubroff, J., Duda, J.E., Ying, G., Tekeli, H., Leon-Sarmiento, F.E.: Taste Function in Early Stage Treated and Untreated Parkinson's Disease. *Journal of Neurology* 262: 547-57, 2015.

Hellman, A.M., Shah, S.P., Pawlowski, S.M., Duda, J.E., Morley, J.F.: Continuous non-invasive monitoring to detect covert autonomic dysfunction in Parkinson's disease. *Parkinsonism and Related Disorders* 21: 723-8, 2015

Nabli, F., Ben Sassi, S., Amouri, R., Duda, J.E., Farrer, M.J., Hentati, F.: Motor phenotype of LRRK2 associated Parkinson's disease: A Tunisian longitudinal study. *Movement Disorders* 30: 253-8, 2015.

Shah, S.P., Glenn, G.L., Hummel, E.M., Hamilton, J.M., Martine, R.R., Duda, J.E., Wilkinson, J.R.: Caregiver tele-support group for Parkinson's disease: A pilot study. *Geriatric Nursing* 36: 207-11, 2015.

Brennan, L., Siderowf, A., Rubright, J.D., Rick, J., Dahodwala, N., Duda, J.E., Hurtig, H., Stern, M., Xie, S.X., Rennert, L., Karlawish, J., Shea, J.A., Trojanowski, J.Q., Weintraub, D. : Development and initial testing of The Penn Parkinson's Daily Activities Questionnaire. *Movement Disorders* in press.

Fitts, W., Weintraub, D., Massimo, L., Chahine, L., Chen-Plotkin, A., Duda, J.E., Hurtig, H.I., Rick, J., Trojanowski, J.Q., Dahodwala, N.: Caregiver report of apathy predicts dementia in Parkinson's disease. *Parkinsonism and Related Disorders* in press.

Pigott, K., Rick, J., Xie, S.X., Hurtig, H., Chen-Plotkin, A., Duda, J.E., Morley, J.F., Chahine, L., Dahodwala, N., Akhtar, R.S., Siderowf, A., Trojanowski, J.Q., Weintraub, D.: Longitudinal study of normal cognition in Parkinson's disease. *Neurology* in press.

Weintraub

Longmire CVF, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG, for the DIADS-2 Research Group. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry 22:14-24, 2014.

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, for the CitAD Research Group. Effect of citalopram on agitation in Alzheimer's disease: the CitAD randomized controlled trial. The Journal of the American Medical Association 311:682-691, 2014.

Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, for the CitAD Research Group. Changes in QTc interval in the citalopram for agitation in Alzheimer's Disease (CitAD) randomized trial. PLOS ONE 9:e98426, 2014.

Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, MD, Zabetian CP, Leverenz JB. People with Parkinson disease and normal MMSE score have a broad range of cognitive performance. Movement Disorders 29:1258-1264, 2014.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu S-C, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurology 71:1405-1412, 2014.

de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson's disease. Neurology 83:1096-1103, 2014.

Mavandadi S, Dobkin R, Mamikonyan E, Sayers S, Ten Have T, Weintraub D. Benefit finding and relationship quality in Parkinson's disease: a pilot dyadic analysis of husbands and wives. Journal of Family Psychology 28:728-734, 2014.

van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, Chahine LM, Dahodwala N, Trojanowski JQ, Roalf DR, Moberg PJ, Weintraub D. Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment and Dementia Rating Scale-2 scores in Parkinson's disease. Movement Disorders 29:1809-1815, 2014.

Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Goldmann Gross R, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin AS. Lower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. Movement Disorders 30:805-812, 2015.

Smith K, Eyal E, Weintraub D, for the ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson's disease in the ADAGIO Study: Effects on non-motor symptoms and tolerability. JAMA Neurology 72:88-95, 2015.

Forjaz MJ, Ayala A, Martinez-Martin P, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Leentjens AFG. Is the Parkinson Anxiety Scale comparable across raters? Movement Disorders 30:545-551, 2015.

Biundo R, Weis L, Facchini S, Formento-Dojot, P, Vallelunga, A, Pilleri, M, Weintraub, D, Antonini, A. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. *Movement Disorders* 30:688-695, 2015.

Weintraub D, Simuni T, Caspell-Garcia C, MS, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, and the Parkinson's Progression Markers Initiative. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson disease. *Movement Disorders* 30:919-927, 2015.

Sharer JD, Leon-Sarmiento FE, Morley JF, Weintraub D, Doty RL. Olfactory dysfunction in Parkinson's disease: positive effect of cigarette smoking. *Movement Disorders* 30:859-862, 2015.

Srivatsal S, Cholerton B, Leverenz JB, MD, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Deerlin VM, Quinn JF, Chung KA, Peterson A, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu S-C, Montine K, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP. Cognitive Profile of LRRK2-related Parkinson's Disease. *Movement Disorders* 30:728-733, 2015.

Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. *Movement Disorders* 30:912-918, 2015.

Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Agüera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Ray Chaudhuri K. Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. *Parkinsonism and Related Disorders* 21:629-634, 2015.

Kim HM, Chiang C, Weintraub D, Schneider LS, Kales H. Treatment changes among elderly patients with dementia treated with antipsychotics. *International Journal of Geriatric Psychiatry* 10.1002/gps.4281, 2015.

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG, for the CitAD Research Group. Time to response to citalopram treatment for agitation in Alzheimer's disease. *American Journal of Geriatric Psychiatry* (in press).

Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG, for the CitAD Research Group. Change in agitation in Alzheimer's disease in the placebo arm of a 9-week controlled trial. *International Psychogeriatrics* (in press).

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ 5, Gwinn K 6, Sutherland M, Martinez M, Heutink P, Williams N, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Alastair J Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover C, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JPA, Singleton AB, on behalf of the Parkinson's Disease Biomarkers Program (PDBP) and the Parkinson's Progression Markers Initiative (PPMI) investigators. Diagnosis of Parkinson's disease on the basis of clinical-genetic classification: a population-based modelling study. *The Lancet Neurology* (in press).

Chahine L, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, and the PARS Investigators. Cognition in individuals at risk for Parkinson's: Parkinson Associated Risk Syndrome Study findings. *Movement Disorders* (in press).

Morley

James F. Morley and John E. Duda: Use of hyposmia and other non-motor symptoms to distinguish between drug-induced Parkinsonism and Parkinson's disease. *Journal of Parkinson's Disease* 4(2): 169-73, 2014.

Lectures: Duda

October, 2014 - "What's Happening to Nigral Neurons in Parkinson's Disease", Neuroscience Seminar, McKnight Brain Institute, University of Florida, Gainesville, Florida.

November, 2014 - "Olfactory dysfunction in sporadic and genetic forms of Lewy body disorders", *Lewy Body Dementia: Current Status, Future Directions*, Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

December 2014 - "Is RLS and NMS of PD" - 10th International Congress on Non-motor Dysfunctions in Parkinson's Disease and Related Disorders, Nice, France

December, 2014 - "Olfactory Dysfunction in LRRK2 Parkinsonism" - 10th International Congress on Non-motor Dysfunctions in Parkinson's Disease and Related Disorders, Nice, France

April, 2015 - "Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains Following Repetitive Traumatic Brain Injury in Swine", American Academy of Neurology Annual Meeting, Washington, D.C.

May, 2015 - "What research tells us about what you should be eating", The 12th Annual Jane C. Wright Patient and Caregiver Symposium of the Parkinson's Disease and Movement Disorders Center of the University of Pennsylvania, Philadelphia, PA.

May, 2015 - Does TBI predispose one to Parkinson's Disease? CNS Injury Conference Series of the Department of Neurosurgery, University of Pennsylvania.

June, 2015 - "Military service and neurodegenerative diseases", 19th International Congress of Parkinson's Disease and Movement Disorders, San Diego, CA

Lectures Weintraub

October, 2014 - "Cognitive Fatigue in Parkinson's Disease", Fatigue in Parkinson's Disease meeting, Parkinson's Disease Foundation; Chicago, Illinois

October, 2014 - "Four Concepts to Practice in Parkinson's Disease: Motor and Non-Motor Complications and Potential Benefits", A Clinician's Guide to Parkinson's Disease and Other Movement Disorders; Cincinnati, Ohio

November, 2014 - "Design and conduct of clinical trials in Lewy body dementia", *Lewy Body Dementia: Current Status, Future Directions*; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

November, 2014 - "CitAD Secondary Analyses: QTc, Psychosis and Time to Response", New Directions in Development of Therapeutics for Agitation and Aggression of AD, Clinical Trials on Alzheimer's Disease Conference; Philadelphia, PA

December, 2014 - "Update on Mild Cognitive Impairment in Parkinson's Disease", 10th International Congress on Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders; Nice, France

December, 2014 -“Clinical Trials for Impulse Control Disorders in Parkinson’s Disease”, 10th International Congress on Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders; Nice, France

January , 2015 - “The Neuropsychiatry of Parkinson’s Disease: Recent Developments”, Department of Neurology Grand Rounds, Rush University; Chicago, Illinois

February , 2015 -“Disease- and Treatment-Related Contributions to Cognition in Parkinson Disease”, National Parkinson Foundation Center of Excellence Leadership Conference; Atlanta Georgia

February, 2015 -“The Neuropsychiatry of Parkinson’s Disease: Recent Developments”, Department of Psychiatry and Behavioral Sciences Friedfeld Lecture, Mount Sinai Beth Israel; New York, New York

February, 2015 -“The Neuropsychiatry of Parkinson’s Disease: Recent Developments”, Fin De Ano Academico 2015: Simposio: Entre Las Neurociencias, Instituto Nacional de Neurologia y Neurocirugia; Mexico City, Mexico

March, 2015 -“Promising Agents and Therapies for Neurobehavioral Complications of Parkinson Disease”, The Cleveland Clinic and Parkinson Study Group 3rd Annual Symposium Shaping the Management of Parkinson’s Disease: Comprehensive Review of Discoveries and Clinical Trials; Fort Lauderdale, Florida

April, 2015 -“Phenomenology and Progression”, Hallucinations in Parkinson’s Disease American, Academy of Neurology Annual Meeting; Washington, D.C.

April, 2015 -“Cognitive Changes in Parkinson’s Disease”, Non-Motor Symptoms: Unraveling the “Invisible” Face of Parkinson’s Disease, New York Academy of Sciences; New York, NY

April, 2015 -“Neuropsychiatry in Parkinson’s Disease: An Update”, VU Medical Center Symposium; Amsterdam, Netherlands

May, 2015 -“Preventing and Treating Neuropsychiatric Symptoms in PD: What’s the Evidence for the Role of Disease, PD treatments, Neurotransmitters, Brain Regions and Pathways?”, 3rd International Conference on Knowledge Gaps in Parkinson’s Disease and Other Movement Disorders; Toronto, Canada

May, 2015 -"PPMI Cognitive-Behavioral Working Group", Parkinson's Progression Markers Initiative (PPMI) Annual Meeting; New York, New York

Poster presentations: Duda/Morley

April, 2015 Duda, J., Harris, J., Kuo, E., Cullen, D.: Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains Following Repetitive Traumatic Brain Injury in Swine. Poster presentation at the American Academy of Neurology Annual Meeting in Washington, D.C

April, 2015 Morley, J., Cheng, G., Dubroff, J., Wilkinson, J., Duda, J.: Can Drug-induced Parkinsonism Reveal Pre-motor Parkinson Disease? Poster presentation at the American Academy of Neurology Annual Meeting in Washington, D.C.

May, 2015 Duda, J., Harris, J., Kuo, E., Cullen, D.: Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains Following Repetitive Traumatic Brain Injury in Swine. Poster presented at the Sylvan M. Cohen Annual Retreat of the Institute of Aging of the University of Pennsylvania in Philadelphia, PA.

May, 2015 Pigott, K., Rick, J., Xie, S.X., Hurtig, H., Chen-Plotkin, A., Duda, J.E., Morley, J.F., Chahine, L., Dahodwala, N., Akhtar, R., Siderowf, A., Trojanowski, J.Q., Weintraub, D.: Longitudinal study of normal cognition in Parkinson's disease. Poster presented at the Sylvan M. Cohen Annual Retreat of the Institute of Aging of the University of Pennsylvania in Philadelphia, PA.

June, 2015 D. Weintraub, K. Pigott, J. Rick, S.X. Xie, H. Hurtig, A. Chen-Plotkin, J. Duda, J. Morley, L. Chahine, N. Dahodwala, R. Akhtar, A. Siderowf, J. Trojanowski: Long-term outcomes for Parkinson's disease patients with normal cognition. 19th International Congress on Parkinson's Disease and Movement Disorders June 2015.

June, 2015 - J.F. Morley, G. Cheng, J. Bubroff, J.R. Wilkinson, J.E. Duda: Underlying dopaminergic deficit in suspected drug-induced Parkinsonism is associated with olfactory impairment. 19th International Congress on Parkinson's Disease and Movement Disorders.

June, 2015 - J.R. Wilkinson, D. Korom-Djakovic, M. Spindler, J. Morley, J. Duda: Patient and provider perception of video telehealth in Parkinson's disease. 19th International Congress on Parkinson's Disease and Movement Disorders.

June, 2015 - M.E. Fullard, D. Weintraub, J.E. Duda, J.F. Morley: Relationship between olfaction, motor and nonmotor symptoms and dopamine transporter binding in de novo PD. 19th International Congress on Parkinson's Disease and Movement Disorders.

June, 2015 - M.E. Fullard, D. Weintraub, J.E. Duda, J.F. Morley: Olfaction and nonmotor symptoms (NMS) in subjects with cans without evidence of dopaminergic deficit (SWEDDs). 19th International Congress on Parkinson's Disease and Movement Disorders June 2015.

Abstracts?

Brennan, L., Rubright, J.D., Rick, J., Dahodwala, N., Duda, J.E., Hurtig, H., Stern, M., Xie, S.X., Rennert, L., Karlawish, J., Shea, J.A., Trojanowski, J.Q., Weintraub, D.: The Pennsylvania daily activities questionnaire: Development, reliability and validity of a new item bank for cognitive instrumental activities of daily living in Parkinson's disease. *Movement Disorders* 30 Suppl 1: 1083, 2015.

Duda, J.E., Keating, C., Kamarck, M., Harris, J.P., Browne, K.D., Cullen, D.K.: Neuronal Plasmalemmal Disruptions Induce Alterations in Dopaminergic Neurons and Alpha-Synuclein Expression Following Traumatic Brain Injury in Swine. *Movement Disorders Late Breaking Abstracts* 2015.

Shah, S.P., Duda, J.E.: The role of nutrition in Parkinson's disease. *Movement Disorders* 30 Suppl 1: 722, 2015.

Shah, S.P., Watson, H.C., Kane, H.M., Duda, J.E.: A pilot study of a plant based diet intervention in Parkinson's disease. *Movement Disorders* 30 Suppl 1: 721, 2015.

Weintraub

June, 2015 Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B, Mamikonyan E, Kales HC. Antipsychotic use in Parkinson disease is associated with increased mortality. 19th International Congress of Parkinson's Disease and Movement Disorders: San Diego, United States

June, 2015 Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson's disease: a randomized, double-blind, placebo-controlled, crossover study. 19th International Congress of Parkinson's Disease and Movement Disorders: San Diego, United States.

June, 2015 Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D. Longitudinal study of normal cognition in Parkinson's disease. 19th International Congress of Parkinson's Disease and Movement Disorders: San Diego, United States.

June, 2015 Chahine L, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, and the PARS Investigators. Cognitive impairment as a feature of prodromal Parkinson's disease: evidence from the PARS study. 19th International Congress of Parkinson's Disease and Movement Disorders: San Diego, United States.

June, 2015 Dubroff J, Nasrallah I, Goldmann Gross R, Rick J, Akhtar RS, Hurtig H, Chen-Plotkin A, Chahine LM, Dahodwala N, Duda JE, Morley JF, Trojanowski JQ, Weintraub D. Amyloid imaging in Parkinson disease: comparison of analytic techniques. 19th International Congress of Parkinson's Disease and Movement Disorders: San Diego, United States.

June, 2015 Smith KM, Xie SX, Weintraub D. MD. Incident impulse control disorder behavior and dopamine transporter imaging in Parkinson disease. 19th International Congress of Parkinson's Disease and Movement Disorders: San Diego, United States.

Morley